title: The febrile neutropenic patient: newer options for empirical therapy.
authors.affiliation: Infectious Disease Section, National Cancer Institute Bethesda, Maryland.
authors.forename: M
authors.initials: M
authors.lastname: Rubin
authors.forename: T
authors.initials: T
authors.lastname: Walsh
authors.forename: K
authors.initials: K
authors.lastname: Butler
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: Lecciones
authors.forename: M
authors.initials: M
authors.lastname: Weinberger
authors.forename: E
authors.initials: E
authors.lastname: Roilides
authors.forename: J
authors.initials: J
authors.lastname: Gress
authors.forename: D
authors.initials: D
authors.lastname: Marshall
authors.forename: P A
authors.initials: PA
authors.lastname: Pizzo
mesh_terms: D000380:Agranulocytosis / Q000150:complications*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D001398:Aztreonam / Q000009:adverse effects / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D015780:Carbapenems / Q000009:adverse effects / Q000627:therapeutic use; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005334:Fever / Q000209:etiology*; D006801:Humans; D009503:Neutropenia / Q000150:complications*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D002511:Cephalosporins; D015363:Quinolones; D001398:Aztreonam